Diabetes.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Insulin glargine: an updated review of its use in the management of diabetes mellitus.Drugs · 2003
   Trial
2. Research Hotspots, Trends, and Molecular Mechanisms of Diabetes and Sarcopenia: A Bibliometric and Bioinformatics Analysis.Endocrine, metabolic & immune disorders drug targets · 2026
   Review
3. Epigenetic Regulation Associated With Sirtuin 1 in Complications of Diabetes Mellitus.Frontiers in endocrinology · 2020
   Review
4. Effect of pulsed high intensity laser therapy on delayed caesarean section healing in diabetic women.Journal of physical therapy science · 2018
   Article
5. Assay method for quality control and stability studies of a new anti-diabetic and anti-dyslipidemic flavone (S002-853).Pharmacognosy magazine · 2015
   Article
6. Possible protective effect of membrane lipid rafts against interleukin-1β-mediated anti-proliferative effect in INS-1 cells.PloS one · 2014
   Article
7. The effect of in vivo mobilization of bone marrow stem cells on the pancreas of diabetic albino rats (a histological & immunohistochemical study).International journal of stem cells · 2013
   Article
8. Diabetic hyperglycemia aggravates seizures and status epilepticus-induced hippocampal damage.Neurotoxicity research · 2009
   Article
9. Environmental contaminants as etiologic factors for diabetes.Environmental health perspectives · 2001
   Review
10. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus.Drugs · 2001
    Review
11. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.Drugs · 2000
    Review
12. Insulin glargine.Drugs · 2000
    Article
13. Hypertension and diabetic retinopathy--what's the story?The British journal of ophthalmology · 1999
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as